Advanced search
Publication Cover
Future Oncology Volume 5, 2009 - Issue 9
Submit an article Journal homepage
125
Views
0
CrossRef citations to date
0
Altmetric
Review

Role of CSF-1 in Progression of Epithelial Ovarian Cancer

Setsuko K ChambersWomen’s Cancers, Arizona Cancer Center, University of Arizona, 1515 N. Campbell Ave., Tucson, AZ85724USA. [email protected]View further author information
Pages 1429-1440 | Published online: 10 Nov 2009

Bibliography

  • Harries M , GoreM: Part I. Chemotherapy for epithelial ovarian cancer-treatment at first diagnosis.Lancet Oncol.3(9), 529–536 (2002).
  • Jemal A , SiegelR, WardEet al.: Cancer statistics, 2008.CA Cancer J. Clin.58(2), 71–96 (2008).
  • Landen CN Jr , BirrerMJ, SoodAK: Early events in the pathogenesis of epithelial ovarian cancer.J. Clin. Oncol.26(6), 995–1005 (2008).
  • Wong KK , LuKH, MalpicaAet al.: Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis.Int. J. Gynecol. Pathol.26(4), 404–409 (2007).
  • Callahan MJ , CrumCP, MedeirosCPet al.: Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.J. Clin. Oncol.25, 3985–3900 (2007).
  • Jarboe EA , FolkinsA, NucciMRet al.: Serous carcinogenesis in the fallopian tube: a descriptive classification.Int. J. Gynecol. Pathol.27(1), 1–9 (2008).
  • Lee Y , MironA, DrapkinRet al.: A candidate precursor to serous carcinoma that originates in the distal fallopian tube.J. Pathol.211(1), 26–35 (2007).
  • Cecchini MG , HofstetterW, HalasyJ, WetterwaldA, FelixR: Role of CSF-1 in bone and bone marrow development.Mol. Reprod. Dev.46, 75–84 (1997).
  • Pollard JW , BartocciA, ArceciRet al.: Apparent role of the macrophage growth factor, CSF-1, in placental development.Nature330, 484–486 (1987).
  • Cohen PE , ZhuL, PollardJW: Absence of colony stimulating factor-1 in osteopetrotic (csfmop/csfmop) mice disrupts estrous cycles and ovulation.Bio. Reprod.56, 110–118 (1997).
  • Sapi E : The role of CSF-1 in normal physiology of mammary gland and breast cancer: an update.Exp. Biol. Med.229(1), 1–11 (2004).
  • Pollard JW , StanleyER, PaulMW: Pleiotropic roles for CSF-1 in development defined by the mouse mutation osteopetrotic.Adv. Dev. Biochem.4, 153–193 (1996).
  • Ryan GR , DaiXM, DominguezMGet al.: Rescue of the colony-stimulating factor 1 (CSF-1)-nullizygous mouse (Csf1op/Csf1op) phenotype with a CSF-1 transgene and identification of sites of local CSF-1 synthesis.Blood98(1), 74–84 (2001).
  • Dai XM , RyanGR, HapelAJet al.: Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects.Blood99(1), 111–120 (2002).
  • Clouser M , HessLM, ChambersSK: Biomarker targets and novel therapeutics.Cancer Treat. Res.149, 85–105 (2009).
  • Stanley ER , BergKL, EinsteinDBet al.: Biology and action of colony-stimulating factor-1.Mol. Reprod. Develop.46(1), 4–10 (1997).
  • Arceci RJ , ShanahanF, StanleyER, PollardJW: Temporal expression and location of colony-stimulating factor (CSF-1) and its receptor in the female reproductive tract are consistent with CSF-1 regulated placental development.Proc. Natl Acad. Sci. USA86, 8818–8822 (1989).
  • Wiktor-Jedrzejczak W , BartocciA, FerranteAWJret al.: Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse.Proc. Natl Acad. Sci. USA87(12), 4828–4832 (1990).
  • Filderman AE , BrucknerA, KacinskiBM, DengN, RemoldHG: Macrophage colony-stimulating factor (CSF-1) enhances invasiveness in CSF-1 receptor positive carcinoma cell lines.Cancer Res.52, 3661–3666 (1992).
  • Ide H , SeligsonDB, MemarzadehLet al.: Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression.Proc. Natl Acad. Sci. USA99(22), 14404–14409 (2002).
  • Kacinski BM , CarterD, MittalKet al.: Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1.Am. J. Pathol.137, 35–147 (1990).
  • Kacinski BM , ChambersSK, StanleyERet al.: The cytokine CSF-1 (M-CSF), whose receptors are expressed by endometrial carcinomas in vivo and in vitro, may also be a circulating tumor marker of neoplastic disease activity for endometrial carcinoma patients.Int. J. Radiat. Oncol. Biol. Phys.19, 619–626 (1990).
  • Kacinski BM , ScataKA, CarterDet al.: FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro.Oncogene6, 941–952 (1991).
  • Rettenmier CW , SaccaR, FurmanWLet al.: Expression of the human c-fms proto-oncogene product (colony-stimulating factor-1 receptor) on peripheral blood mononuclear cells and choriocarcinoma cell lines.J. Clin. Invest.77, 1740–1746 (1989).
  • Chambers SK , IvinsCM, KacinskiBM, HochbergRB: An unexpected effect of glucocorticoids on stimulation of c-fms proto-oncogene expression in choriocarcinoma cells expressing little glucocorticoid receptor.Am. J. Obstet. Gynecol.190, 974–985 (2004).
  • Keshava N , GubbaS, TekmalRR: Overexpression of macrophage colony-stimulating factor (CSF-1) and its receptor, c-fms, in normal ovarian granulosa cells leads to cell proliferation and tumorigenesis.J. Soc. Gynecol. Invest.6(1), 41–49 (1999).
  • Chambers SK , KacinskiBM, IvinsCM, CarcangiuML: Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.Clin. Cancer Res.3(6), 999–1007 (1997).
  • Maher MG , SapiE, TurnerBet al.: Prognostic significance of colony-stimulating factor receptor expression in ipsilateral breast cancer recurrence.Clin. Cancer Res.4, 1851–1856 (1998).
  • Price FV , ChambersSK, ChambersJTet al.: CSF-1 concentration in primary ascites of ovarian cancer is a significant predictor of survival.Am. J. Obstet. Gynecol.68, 520–527(1993).
  • Scholl S , BascouCH, MosseriVet al.: Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer.Br. J. Cancer62, 342–346 (1994).
  • Toy EP , ChambersJT, KacinskiBM, FlickMB, ChambersSK: The activated macrophage colony stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma.Gynecol. Oncol.80, 194–200 (2001).
  • Tang R , KacinskiB, ValidirePet al.: Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells?J. Cell. Biochem.44, 189–198 (1990).
  • Kluger HM , Dolled-FilhartM, RodovS, KacinskiBM, CampRL, RimmDL: Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis.Clin. Cancer Res.10(1 Pt 1), 173–177 (2004).
  • Baiocchi G , KavanaghJJ, TalpazM, WhartonJT, GuttermanJU, KurzrockR: Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies.Cancer67(4), 990–996 (1991).
  • Toy EP , AzodiM, FolkNL, ZitoCM, ZeissCJ, ChambersSK: Enhanced ovarian cancer tumorigenesis and metastasis by the macrophage colony stimulating factor (CSF-1).Neoplasia11(2), 136–144 (2009).
  • Sapi E , FlickMB, RodovSet al.: Independent regulation of invasion and anchorage-independent growth by different autophosphorylation sites of the macrophage colony-stimulating factor 1 receptor.Cancer Res.56, 5704–5712 (1996).
  • Kacinski BM , StanleyER, CarterDet al.: Circulating levels of CSF-1 (M-CSF) a lymphohematopoietic cytokine may be a useful marker of disease status in patients with malignant ovarian neoplasms.Int. J. Radiat. Oncol. Biol. Phys.17, 159–164 (1989).
  • Skates SJ , HorickN, YuYet al.: Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15–13, CA 72–74, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.J. Clin. Oncol.22, 4059–4066 (2004).
  • Zhang Z , YuY, XuFet al.: Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.Gynecol. Oncol.107, 526–531 (2007).
  • Flick MB , SapiE, PerrottaPLet al.: Recognition of activated CSF-1 receptor in breast carcinomas by a tyrosine 723 phosphospecific antibody.Oncogene14, 2553–2561 (1997).
  • Scholl SM , MosseriV, TangR, PouillartP: Expression of colony stimulating factor-1 and its receptor (the protein product of c-fms) in invasive breast tumor cells.Ann. NY Acad. Sci.698, 131–135 (1993).
  • Wrobel CN , DebnathJ, LinE, BeausoleilS, RousselMF, BruggeJS: Autocrine CSF-1R activation promotes Src-dependent disruption of mammary epithelial architecture.J. Cell Biol.165(2), 263–273 (2004).
  • Lin EY , NguyenAV, RussellRG, PollardJW: Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy.J. Exp. Med.193(6), 727–740 (2001).
  • Toy EP , BonafeN, SavluAet al.: Correlation of tumor phenotype with c-fms proto-oncogene expression in an in vivo intraperitoneal model for experimental human breast cancer metastasis.Clin. Exp. Metast.22(1), 1–9 (2005).
  • Tamimi RM , BruggeJS, FreedmanMLet al.: Circulating colony stimulating factor-1 and breast cancer risk.Cancer Res.68(1), 18–21 (2008).
  • Scholl SM , PalludC, BeuvonFet al.: Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis.J. Natl Cancer Inst.86, 120–126 (1994).
  • Bonafe N , Gilmore-HebertM, FolkNL, AzodiM, ZhouY, ChambersSK: Glyceraldehyde-3-phosphate dehydrogenase binds to the AU-rich 3´ UTR of CSF-1 mRNA in human ovarian cancer cells: possible role in CSF-1 post-transcriptional regulation and tumor phenotype.Cancer Res.65(9), 3762–3771 (2005).
  • Chambers SK , WangY, GertzRE, KacinskiBM: Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase.Cancer Res.55(7), 1578–1585 (1995).
  • Woo HH , ZhouY, YiXet al.: Regulation of non AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer.Oncogene28(9), 1176–1189 (2009)
  • Bruckner A , FildermanAE, KirchheimerJC, BinderBR, RemoldHG: Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1.Cancer Res.52, 3043–3047 (1992).
  • Hamilton JA , WhittyGA, StantonH, MeagerA: Effects of macrophage-colony stimulating factor on human monocytes: induction of expression of urokinase-type plasminogen activator, but not of secreted prostaglandin E2, interleukin-6, interleukin-1, or tumor necrosis factor-α.J. Leuk. Biol.53, 707–714 (1993).
  • Kuhn W , SchmalfeldtB, ReuningUet al.: Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.Br. J. Cancer79(11–12), 1746–1751 (1999).
  • van der Burg ME , Henzen-LogmansSC, BernsEM, van PuttenWL, KlijnJG, FoekensJA: Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors.Int. J. Cancer69(6), 475–479 (1996).
  • Saldanha RG , MolloyMP, BdeirKet al.: Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy.J. Proteome Res.6(3), 1016–1028 (2007).
  • Chambers SK , IvinsCM, CarcangiuML: Urokinase-type plasminogen activator in epithelial ovarian cancer: a poor prognostic factor, associated with advanced stage.Int. J. Gynecol. Cancer8, 242–250 (1998).
  • Chambers SK , IvinsCM, CarcangiuML: Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients.Int. J. Cancer79, 449–454 (1998).
  • Wilhelm O , SchmittM, HohlS, SenekowitschR, GraeffH: Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice.Clin. Exp. Metast.13, 296–302 (1995).
  • Towle MJ , LeeA, MaduakorECet al.: Inhibition of urokinase by 4-substituted Benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.Cancer Res.53, 2553–2559 (1993).
  • Nowicki A , SzenajchJ, OstrowskaGet al.: Impaired tumor growth in colony-stimulating factor 1 (CSF-1)-deficient, macrophage-deficient op/op mouse: evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma.Int. J. Cancer65(1), 112–119 (1996).
  • Aharinejad S , AbrahamD, PaulusPet al.: Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice.Cancer Res.62(18), 5317–5324 (2002).
  • Aharinejad S , PaulusP, SioudM, HofmannM, ZinsK, SchaferR: Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice.Cancer Res.64, 5378–5384 (2004).
  • Paulus P , StanleyER, SchaferR, AbrahamD, AharinejadS: Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts.Cancer Res.66(8), 4349–4356 (2006).
  • Pollard JW : Tumour-educated macrophages promote tumour progression and metastasis.Nat. Rev. Cancer4, 71–78 (2004).
  • Hagemann T , WilsonJ, BurkeFet al.: Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype.J. Immunol.176(8), 5023–5032 (2006).
  • Hagemann T , WilsonJ, KulbeHet al.: Macrophages induce invasiveness of epithelial cancer cells via NF-κB and JNK.J. Immunol.175(2), 1197–1205 (2005).
  • Hidaka T , AkadaS, TeranishiAet al.: Mirimostim (macrophage colony-stimulating factor; M-CSF) improves chemotherapy-induced impaired natural killer cell activity, Th1/Th2 balance, and granulocyte function.Cancer Sci.94(9), 814–820 (2003).
  • Mizutani K , TakeuchiS, OhashiYet al.: Clinical usefulness of macrophage colony-stimulating factor for ovarian cancers: long-term prognosis after five years.Oncol. Rep.10(1), 127–131 (2003).
  • Chambers SK , Gilmore-HebertM, WangY, RodovS, BenzEJ, KacinskiBM: Post-transcriptional regulation of CSF-1 and CSF-1 receptor gene expression during inhibition of phorbol-ester induced monocytic differentiation by dexamethasone and cyclosporin A: potential involvement of a destabilizing protein.Exp. Hematol.21, 1328–1334 (1993).
  • de Wit H , EsselinkMT, HalieMR, BallengaE: Differential regulation of M-CSF and IL-6 expression in monocytic cells.Br. J. Haematol.86, 259–264 (1994).
  • Ernst TJ , RitchieAR, DemetriGD, GriffinJD: Regulation of granulocyte-and monocyte-colony stimulating factor mRNA levels in human blood monocytes is mediated primarily at a post-transcriptional level.J. Biol. Chem.264, 5700–5703 (1989).
  • Horiguchi J , SaribanE, KufeD: Transcriptional and posttranscriptional regulation of CSF-1 gene expression in human monocytes.Mol. Cell. Biol.8, 3951–3954 (1988).
  • Sherman ML , WeberBL, DattaR, KufeDW: Transcriptional and posttranscriptional regulation of macrophage-specific colony stimulating factor gene expression by tumor necrosis factor.J. Clin. Invest.85, 442–447 (1990).
  • Suen Y , LeeSM, SchreursJ, KnoppelE, CairoMS: Decreased macrophage colony-stimulating factor mRNA expression from activated cord versus adult mononuclear cells: altered posttranscriptional stability.Blood84, 4269–4277 (1994).
  • Borycki A , LenormundJ, GuillierM, LeibovitchSA: Isolation and characterization of a cDNA clone encoding for rat CSF-1 gene. Post-transcriptional repression occurs in myogenic differentiation.Biochim. Biophys. Acta1174, 143–152 (1993).
  • Falkenburg JHF , HarringtonMA, de PausRAet al.: Differential transcriptional and postranscriptional regulation of gene expression of the colony-stimulating factors by interleukin-1 and fetal bovine serum in murine fibroblasts.Blood78, 658–665 (1991).
  • Rubin J , FanD, WadeAet al.: Transcriptional regulation of the expression of macrophage colony stimulating factor.Mol. Cell Endocrinol.160, 193–202 (2000).
  • Cheadle C , FanJ, Cho-ChungYSet al.: Stability regulation of mRNA and the control of gene expression.Ann. NY Acad. Sci.1058, 196–204 (2005).
  • Colegrove-Otero LJ , MinshallN, StandartN: RNA-binding proteins in early development.Crit. Rev. Biochem. Mol. Biol.40, 21–73 (2005).
  • Bassell GJ , KelicS: Binding proteins for mRNA localization and local translation, and their dysfunction in genetic neurological disease.Curr. Opin. Neurobiol.14, 574–578 (2004).
  • Musunuru K : Cell-specific RNA-binding proteins in human disease.Trends Cardiovasc. Med.13, 188–195 (2003).
  • Gouble A , GrazideS, MeggettoF, MercierP, DelsolG, MorelloD: A new player in oncogenesis: AUF1/hnRNPD overexpression leads to tumorigenesis in transgenic mice.Cancer Res.62, 1489–1495 (2002).
  • Tessier CR , DoyleGA, ClarkBA, PitotHC, RossJ: Mammary tumor induction in transgenic mice expressing an RNA-binding protein.Cancer Res.64, 209–214 (2004).
  • Stoecklin G , GrossB, MingX-F, MoroniC: A novel mechanism of tumor suppression by destabilizing AU-rich growth factor mRNA.Oncogene22(23), 3554–3561 (2003).
  • Sachs AB : Messenger RNA degradation in eukaryotes.Cell74, 413–421 (1993).
  • Xie X , LuJ, KulbokasEJet al.: Systematic discovery of regulatory motifs in human promoters and 3´UTRs by comparison of several mammals.Nature434(7031), 338–345 (2005).
  • Zhu S , WuH, WuF, NieD, ShengS, MoY-Y: MicroRNA-21 targets tumor suppressor genes in invasion and metastasis.Cell Res.18, 350–359 (2008).
  • Ma L , Teruya-FeldsteinJ, WeinbergRA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.Nature449(7163), 682–688 (2007).
  • Tavazoie SF , AlarconC, OskarssonTet al.: Endogenous human microRNAs that suppress breast cancer metastasis.Nature451(7175), 147–152 (2008).
  • Mitchell PS , ParkinRK, KrohEMet al.: Circulating microRNAs as stable blood-based markers for cancer detection.Proc. Natl Acad. Sci. USA105(30), 10513–10518 (2008).
  • Sorrentino A , LuiCG, AddarioA, PeschleC, ScambiaG, FerliniC: Role of microRNAs in drug-resistant ovarian cancer cells.Gynecol. Oncol.111(3), 478–486 (2008).
  • Chambers SK , KacinskiBM: Messenger RNA decay of macrophage colony-stimulating factor in human ovarian carcinomas in vitro.J. Soc. Gynecol. Investig.1, 310–316 (1994).
  • Price LKH , ChoiHU, RosenbergL, StanleyER: The predominant form of secreted colony stimulating factor-1 is a proteoglycan.J. Biol. Chem.267, 2190–2199 (1992).
  • Ramakrishnan S , XuFJ, BrandtSJ, NiedelJE, BastRCJr, BrownEL: Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines.J. Clin. Invest.83(3), 921–926, (1989).
  • Shaw G , KamenR: A conserved AU sequence from the 3´ untranslated region of GM-CSF mRNA mediates selective mRNA degradation.Cell46, 659–667 (1986).
  • Wong GG , TemplePA, LearyACet al.: Human CSF-1: molecular cloning and expression of 4‑kb cDNA encoding the human urinary protein.Science235, 1504–1508 (1987).
  • Vasudevan S , SteitzJA: AU-rich-element-mediated upregulation of translation by FXR1 and argonaute 2.Cell128(6), 1105–1118 (2007).
  • Fan H , VillegasC, HuangA, WrightJA: Suppression of malignancy by the 3´ untranslated regions of ribonucleotide reductase R1 and R2 messsenger RNAs.Cancer Res.56, 4366–4369 (1996).
  • Meijlink F , CurranT, MillerAD, VermaIM: Removal of a 67-base-pair sequence in the noncoding region of proto-oncogene c-fos converts it to a transforming gene.Proc. Natl Acad. Sci. USA82, 4987–4991 (1985).
  • Rastinejad F , ConboyMJ, RandoTA, BlauHM: Tumor suppression by RNA from the 3´ untranslated region of α-tropomyosin.Cell75, 1107–1117 (1993).
  • Wodnar FA , MoroniC: Regulation of interleukin 3 mRNA expression in mast cells occurs at the posttranscriptional level and is mediated by calcium ions.Proc. Natl Acad. Sci. USA87, 777–781 (1990).
  • Rastinejad F , BlauHM: Genetic complementation reveals a novel regulatory role for 3´ untranslated regions in growth and differentiation.Cell72, 903–917 (1993).
  • Zhou Y , YiX, StofferJBet al.: The multifunctional protein glyceraldehyde-3-phosphate dehydrogenase is both regulated and controls CSF-1 mRNA stability in ovarian cancer.Mol. Cancer Res.6(8), 1375–1384 (2008).
  • Sirover MA : New nuclear functions of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in mammalian cells.J. Cell Biochem.95, 45–52 (2005).
  • Xie Y , ChenC, HumeDA: Transcriptional regulation of c-fms gene expression.Cell Biochem. Biophys.34, 1–16 (2001).
  • Weber B , HoriguchiJ, LuebbersR, ShermanM, KufeD: Posttranscriptional stabilization of c-fms mRNA by a labile protein during human monocytic differentiation.Mol. Cell Biol.9, 769–775 (1989).
  • Stone RM , ImamuraK, DattaR, ShermanML, KufeDW: Inhibition of phorbol ester-induced monocytic differentiation and c-fms gene expression by dexamethasone: potential involvement of arachidonic acid metabolites.Blood76, 1225–1232 (1990).
  • Sapi E , FlickMB, Gilmore-HebertM, RodovS, KacinskiBM: Transcriptional regulation of the c-fms (CSF-1R) proto-oncogene in human breast carcinoma cells by glucocorticoids.Oncogene10, 529–542 (1995).
  • Kacinski BM , FlickMB, SapiE: RU-486 can abolish glucocorticoid-induced increases in CSF-1 receptor expression in primary human breast carcinoma specimens.J. Soc. Gynecol. Investig.8, 114–116 (2001).
  • Flick MB , SapiE, KacinskiBM: Hormonal regulation of the c-fms proto-oncogene in breast cancer cells is mediated by a composite glucocorticoid response element.J. Cell Biochem.85, 10–23 (2002).
  • Chambers SK , WangY, Gilmore-HebertM, KacinskiBM: Post-transcriptional regulation of c-fms proto-oncogene expression by dexamethasone and of CSF-1 in human breast carcinomas in vitro.Steroids59, 514–522 (1994).
  • Brennan CM , SteitzJA: HuR and mRNA stability.Cell. Mol. Life Sci.58(2), 266–277 (2001).
  • Mazan-Mamczarz K , HagnerPR, CorlSet al.: Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype.Oncogene27(47), 6151–6163 (2008).
  • Denkert C , WeichertW, PestSet al.: Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression.Cancer Res.64, 189–195 (2004).
  • Erkinheimo TL , LassusH, SivulaAet al. Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res. 63(22), 7591–7594 (2003).
  • Heinonen M , BonoP, NarkoKet al.: Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma.Cancer Res.65, 2157–2161 (2005).
  • Lopez de Silanes I , FanJ, YangXet al.: Role of the RNA-binding protein HuR in colon carcinogenesis.Oncogene22(46), 7146–7154 (2003).
  • Nabors LB , GillespieGY, HarkinsL, KingPH: HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3´ untranslated regions of cytokine and angiogenic factor mRNAs.Cancer Res.61(5), 2154–2161 (2001)
  • Yi X , ZhouY, ZhengW, ChambersSK: HuR expression in the nucleus correlates with high histologic grade and poor disease-free survival in ovarian cancer.Aust. NZ J. Obstet. Gynaecol.49(1), 93–98 (2009).
  • Alberts DS , LiuPY, WilczynskiSPet al.: Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).Int. J. Gynecol. Cancer17(4), 784–788 (2007).
  • Kluger HM , KlugerYGilmore-HebertMet al.: cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model.Lab. Investig.84, 320–331 (2004).
  • Hussain MM , KotzH, MinasianLet al.: Phase II trial of carboxyamidotriazole inpatients with relapsed epithelial ovarian cancer.J. Clin. Oncol.21(23), 4356–4363 (2003).
  • Berkenblit A , MatulonisUA, KroenerJFet al.: A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a Phase I trial.Gynecol. Oncol.99(1), 50–57 (2005).
  • Ghamande SA , SilvermanMH, HuhWet al.: A Phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.Gynecol. Oncol.111(1), 89–94 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.